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Trimethylamine N-oxide (TMAO) is produced when trimethylamine, a waste product of gut mi-
crobes, is converted via hepatic flavin monooxygenases. As TMAO is a potential causative factor 
in various cardiovascular diseases (CVDs) considerable research interest has arisen on its use as a 
biomarker. Higher TMAO levels are associated with future risk of both incident CVD in the gener-
al population and established CVD, including stroke. The addition of TMAO into models with 
traditional risk factors significantly improved the prediction of future CVD risk. TMAO promotes 
atherosclerosis and is associated with platelet hyperreactivity and inflammation, which are in 
turn associated with the development of stroke and its secondary consequences. Additionally, 
TMAO may play a key mediator role in the relationship between the diet, gut microbiota, and 
CVD development. Compelling evidence suggesting that TMAO is both a risk factor and prognos-
tic marker of stroke and CVD. Potential therapeutic strategy of diet and drugs in reducing TMAO 
levels have emerged. Thus, TMAO is a novel biomarker and target in stroke and CVD prevention.
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Introduction
An increasing body of evidence suggests that the human intes-
tinal gut microbiota—composed of tens of trillions of bacteria—
and microbiota-derived metabolites play roles in various diseas-
es, including cardiovascular disease (CVD) and stroke.1 The hu-
man microbiota includes at least 1,000 species of known bacte-
ria harboring more than 3 million genes (150 times more genes 
than the human genome). The brain and gut are connected by a 
network of neurons, forming a complex microbiota-gut-brain 
axis that exhibits strong bi-directional interactions.
Accumulating evidence also suggests that the intestinal mi-
crobiota plays an important role in the pathophysiology and 
outcome of stroke. Ischemic stroke alters the composition of 
the intestinal microbiota. Conversely, the intestinal microbiota 
can modulate the outcome of stroke and plays a role in the 
pathogenesis of stroke. Clinical and experimental studies have 
reported that the gut microbiota is associated with risk factors 
for stroke such as hypertension, diabetes, and obesity.2
Clinically, risk stratification for stroke remains a challenge. 
Clinical scoring algorithms have been developed to aid in the 
prediction of adverse events. Biomarkers can provide additional 
clinically useful information. The interest in combining clinical 
and biochemical markers for use in precision medicine is there-
fore growing,3,4 and metabolomics is a relatively new and 
promising technology for identifying useful biomarkers.5
Trimethylamine N-oxide (TMAO) is a metabolite generated 
as a waste product of the gut microbiota which is associated 
with both CVD and stroke. Increased TMAO levels have been 
linked to increased risk of incident major adverse cardiovascu-
lar events (MACEs) independent of traditional cardiovascular 
risk factors. Moreover, TMAO is directly linked to poor out-
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comes in patients with CVD.6,7 Despite numerous studies dem-
onstrated its harmful effects, several studies have suggested 
that TMAO plays a protective role. Other studies have suggest-
ed that TMAO is a marker of a disruption in homeostasis rather 
than a causative or protective factor.8,9 This review will discuss 
the current research on the production of TMAO, its associa-
tion with CVD and stroke and related pathogenic mechanisms, 
analytical methods, and potential therapeutic strategies in ad-
dition to areas of continued debate.
Production of TMAO
TMAO is formed via a two-step process, the meta-organismal 
diet/microbiota dependent pathway and human endogenous 
pathway. In the first step, trimethylamine (TMA) is generated 
from the dietary nutrients (e.g., choline, phosphatidylcholine, L-
carnitine) by the activity of gut microbiota TMA lyases. In the 
second step, TMA is absorbed and oxidized to TMAO by hepatic 
flavin-containing monooxygenases (FMOs). The specific activity 
of FMO3 for oxidizing TMA is >10 times that of FMO1.10 FMO3 
plays an important role in the regulation of blood glucose and 
cholesterol levels in addition to bile acid metabolism.11 Fish 
odor syndrome (trimethylaminuria) is a genetic disease associ-
ated with mutations in the FMO3 gene. Loss-of-function mu-
tations in FMO3 lead to increased levels of volatile TMA, which 
has a fish-like odor (Figure 1).9 
The TMA-containing nutrients choline, phosphatidylcholine, 
and L-carnitine are subsequently degraded by a TMA lyase pro-
duced by specific intestinal bacteria. The microbiota plays a 
critical role in TMA formation, as evidenced by antibiotic 
knockdown studies clearly demonstrating that TMAO is not 
formed in the absence of a microbiota.7 Microbial transplanta-
tion studies showed that potential TMAO production is a trans-
missible trait linked with atherosclerosis and thrombosis, sug-
gesting that TMAO is a factor in atherogenesis and thrombosis 
risk.12 Although speciﬁc members of the gut microbiota in-
volved in TMA generation have not been identiﬁed, previous 
studies have reported a relationship between plasma TMAO 
levels and members of the phylum Tenericutes and genus De-
sulfovibrio. The general function of TMAO in mammals has yet 
to be elucidated; however, in saltwater fish and crustaceans, 
TMAO serves as a major osmolyte and chaperone that stabilizes 
the protein structure, countering the denaturing effects of urea 
and high ambient water pressure.13
Diet and TMAO
Diet profoundly affects the gut microbiota and can alter the 
overall bacterial composition.14 High consumption of meat, 
choline, and L-carnitine increases the formation of TMAO. 
Phosphatidylcholine is a major dietary source of choline com-
monly found in the Western diet such as red meat, eggs, and 
other meat products.15 In healthy volunteers given a phospha-
tidylcholine challenge before and after antibiotic-mediated 
suppression of the gut microbiota, choline metabolites in-
creased after the phosphatidylcholine challenge. The antibiotic 
treatment suppressed TMAO generation and TMAO formation 
resumed when the antibiotics were withdrawn. These data in-
dicate that dietary phosphatidylcholine intake is associated 
with increased TMAO levels.7 
Signiﬁcant diet-host interactions also affect TMAO produc-
tion. Inter-individual variations in circulating and urinary 
TMAO concentrations have been reported following the con-
sumption of eggs and choline supplements.16,17 Additionally, 
blood TMAO concentrations increased after a high-fat diet.18 
TMAO and CVD
The results of recent clinical studies suggest a correlation be-
tween elevated plasma TMAO levels and the risk of stroke, atri-
al fibrillation, diabetes, congestive heart failure and chronic 
kidney, coronary artery, and peripheral artery disease. TMAO is 
also an independent and dose-dependent risk factor for CVD, 
and elevated systemic TMAO concentrations are correlated 
with an increased future risk of cardiovascular events and all-
cause mortality.
TMAO and stroke 
Relatively few studies have addressed the relationship between 
TMAO and stroke. A nested case-control study of a hypertensive 
Chinese population showed that higher TMAO levels were associ-
ated with an increased risk of first stroke. Patients in the upper 
tertiles had a 34% higher risk of first stroke than those in the 
lowest tertiles. They also found that patients with low folate and 
high TMAO had the highest rate of stroke.19 In patients with first-
ever stroke, elevated TMAO levels exhibit a dose-dependent asso-
ciation with the risk of recurrent stroke and subsequent cardio-
vascular events. This relationship remains even after adjusting for 
traditional cerebrovascular risk factors and initial stroke severity. 
Blood TMAO concentration is closely related to the number of 
proinflammatory intermediate CD14++/CD16+ monocytes.12 
A case-control study of Chinese patients with stroke and 
transient ischemic attack (TIA) showed signiﬁcant dysbiosis of 
the gut microbiota. Importantly, stroke and TIA patients exhib-
ited lower plasma TMAO concentrations than control patients 
with asymptomatic atherosclerosis. The authors explained that 
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Figure 1. Production of trimethylamine N-oxide (TMAO) and association with atherosclerosis and thrombosis resulting in cardiovascular diseases. Trimethyl-
amine (TMA) is generated by the action of TMA lyases in the gut microbiota from dietary TMA-containing nutrients (e.g., choline, phosphatidylcholine, L-car-
nitine). Then, TMA is rapidly further oxidized to TMAO by hepatic flavin-containing monooxygenases (FMOs). TMAO promotes macrophage foam cell forma-
tion, development of platelet hyperreactivity, altered bile acids and cholesterol transport, and activation of the inflammatory pathway. All factors are associat-
ed with an increased risk of cardiovascular diseases including stroke, myocardial infarction, congestive heart failure, and chronic kidney disease. 
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they examined the TMAO level in patients who already had 
stroke or TIA, the level of TMAO was quite low compared to a 
previous Western study, and the treatment of stroke or TIA may 
reduce the TMAO levels.20 
A multicenter study reported that plasma TMAO levels be-
fore carotid artery stenting were signiﬁcantly higher in patients 
with new lesions on post-stenting diffusion-weighted image 
(DWI) than in patients without new lesions. After adjusting for 
possible confounders, elevated plasma TMAO levels remained 
an independent predictor of new lesions on DWI after carotid 
artery stenting.6 Moreover, increased serum TMAO levels have 
been associated with increased carotid intima-media thickness 
in subjects at risk for type 2 diabetes, independent of insulin 
resistance, visceral obesity, and fatty liver. Following a lifestyle 
modification intervention, the carotid intima-media thickness 
signiﬁcantly decreased in subjects who exhibited the greatest 
decrease (>20%) in TMAO levels.21
TMAO and atrial fibrillation
A recent study demonstrated a positive association between 
plasma TMAO levels and long-term incident atrial fibrillation in 
patients with suspected stable angina. This finding was vali-
dated in a community cohort of elderly participants.22 
TMAO and diabetes
Patients with diabetes typically have higher TMAO concentra-
tions, MACEs, and mortality risk independent of traditional risk 
factors, renal function, or glycemic control than the healthy 
controls.23 In contrast, a case–control study showed that pa-
tients with high baseline TMAO levels had a lower risk of de-
veloping diabetes after adjustments were made.24 
TMAO and coronary artery disease
Over a 3-year follow-up period of patients who underwent 
elective coronary angiography, the plasma TMAO concentra-
tions were positively associated with the rate of MACEs. Pa-
tients in the highest quartile of circulating TMAO level exhibit-
ed a 2.5-fold higher risk of MACEs than patients in the lowest 
quartile, even after adjustment for traditional risk factors.7 In 
acute myocardial infarction, TMAO concentrations were also 
associated with a poor prognosis (death/myocardial infarction) 
at 2 years (hazard ratio [HR], 1.21; 95% confidence interval 
[CI], 1.03 to 1.43) but was not able to predict death/myocardial 
infarction at 6 months (HR, 1.19; 95% CI, 0.96 to 1.48).3 
An optical coherence tomography study of patients with 
acute coronary syndrome demonstrated that TMAO levels were 
associated with the vulnerability and progression of coronary 
plaque and the long-term risks of cardiovascular events in pa-
tients with acute coronary syndrome.25 Plasma TMAO concen-
trations were significantly higher in patients with ST-segment 
elevation myocardial infarction with plaque rupture than in 
patients exhibiting plaque erosion. The authors suggested that 
TMAO could be a useful biomarker for predicting plaque rup-
ture in patients with a history of acute myocardial infarction.26
TMAO and heart failure
Data also suggest that high TMAO levels are associated with 
the development and progression of heart failure. Patients with 
stable heart failure have higher TMAO levels than the healthy 
subjects. In patients with acute heart failure, TMAO was found 
to be associated with in-hospital mortality and poor prognosis 
at 1 year. The authors suggest that both TMAO and N-terminal 
pro-brain natriuretic peptide provide additional prognostic in-
formation.27 Interestingly, following the adjustment for renal 
function markers such as the estimated glomerular filtration 
rate and urea, TMAO was no longer significantly associated 
with these outcomes.28 Patients with chronic heart failure have 
elevated TMAO levels, which are positively correlated with the 
disease severity and adverse outcomes during follow-up.29 Ad-
ditionally, these patients with elevated circulating TMAO levels 
have a poorer prognosis at 5 years.30 
TMAO and chronic kidney disease
Patients with chronic kidney disease exhibit increased blood 
TMAO concentrations, and this is inversely associated with the 
glomerular ﬁltration rate. Elevated TMAO levels are strongly 
associated with decreased renal function. Dialysis can effec-
tively remove TMAO from the circulation in patients with ele-
vated TMAO levels, and TMAO levels were within normal range 
after renal transplantation.31,32 In patients with advanced 
chronic kidney disease, an elevated TMAO level was found to 
be independently associated with MACE risk after adjustment 
for cardiovascular risk factors.32,33 
Studies examining the relationship between TMAO levels 
and cardiovascular outcomes have identified kidney function 
as an important confounder. Patients with CVD typically exhibit 
a declining kidney function, which in turn is a well-established 
risk factor for exacerbation of CVD. Elevated TMAO levels are 
thought to be indicative of renal medullary damage resulting 
from CVD-associated hypertension.17
TMAO and peripheral arterial obstructive disease
TMAO was found to be a signiﬁcant predictor of a 5-year all-
cause mortality risk among patients with stable peripheral ar-
tery diseases, including lower extremity peripheral artery dis-
ease and renal, mesenteric, and carotid artery stenosis. When 
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TMAO was included as a covariate in risk analyses, a signiﬁcant 
improvement in the accuracy of risk estimations was noted.15
TMAO and Alzheimer’s disease
The gut microbiota can influence the aging process and cogni-
tive dysfunction. Plasma TMAO levels increased in both the el-
derly and aged mice. TMAO promotes neuronal senescence, 
synapse damages, and reduces the synaptic plasticity.34 A recent 
study showed that cerebrospinal fluid TMAO levels were elevat-
ed in individuals with Alzheimer’s disease (AD), and an elevated 
cerebrospinal fluid TMAO level is associated with elevated AD 
pathology and neuronal degeneration. TMAO may play a role in 
AD pathology by promoting cerebrovascular disease as a vascu-
lar risk factor is common in AD patients, and cerebrovascular 
pathology frequently coexists with AD pathology.35 
Mechanism of TMAO associated 
atherosclerosis and thrombosis
The mechanism by which TMAO promotes atherosclerosis is 
poorly understood. Several mechanisms have been proposed, in-
cluding promotion of foam cell formation via TMAO-mediated 
increased expression of scavenger receptors on macrophages, 
changes in cholesterol, sterol, bile acid metabolism, sterol trans-
porters, and activation of pro-inflammatory pathways.25
Foam cell formation
Wang et al.36 were the first to report a potential mechanistic 
link between TMAO and development of atherosclerosis. They 
reported that TMAO promotes macrophage foam cell forma-
tion that is associated with increased expression of two scav-
enger receptors of CD36 and scavenger receptors class A1 (SR-
A1).36 Another group reported that the susceptibility to athero-
sclerosis can be transferred via transplantation of gut microbes 
in a mouse model.37 Suppression of TMAO generation using a 
small-molecule inhibitor of microbial TMA production inhibits 
atherosclerosis, and animal model studies demonstrated that 
suppression of FMO3 activity leads to both a reduction in 
TMAO levels and inhibition of atherosclerosis.11
Platelet hyperreactivity and thrombosis
Studies conducted on animal models and healthy volunteers in-
dicated that TMAO contributes directly to platelet hyperreactivi-
ty and increases the risk for thrombosis. Sub-maximal stimulus-
dependent platelet activation by multiple agonists was enhanced 
by direct exposure of the platelets to TMAO in a process mediat-
ed by an augmented release of Ca2+ from intracellular stores. 
TMAO-mediated modulation of platelet hyperreactivity and 
thrombosis potential was confirmed in a microbial transplanta-
tion study using the germ-free mice. These data suggest that 
therapies targeting TMAO could have beneficial anti-thrombotic 
effects without increased risk of bleeding complications.38 
Cholesterol metabolism
The bile acid pathway plays an important role in removing excess 
cholesterol from the circulation. Disruption of normal bile acid 
synthesis and metabolism has been linked to an increased risk of 
atherosclerosis. TMAO plays a signiﬁcant role in cholesterol me-
tabolism in the bile acid compartments, affecting the metabo-
lism of cholesterol and sterol in macrophages, the liver and the 
intestines. A signiﬁcant reduction in cholesterol absorption and 
hepatic expression of bile acid synthetic enzymes including cyto-
chrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1) and 
cytochrome P450, family 27, subfamily a, polypeptide 1 (Cy-
p27a1) was noted.8 The mice which fed on a diet supplemented 
with TMAO, carnitine, or choline had decreased reverse choles-
terol transport. Suppression of the intestinal microbiota by treat-
ment with oral broad-spectrum antibiotics completely blocks the 
suppression of reverse cholesterol transport.39 
Inflammation
Among the many deleterious effects of ischemic stroke, in-
creased inflammation can lead to a substantial secondary 
damage following stroke. TMAO is known to activate the pro-
inflammatory pathways and promote vascular inflammation 
and endothelial cell dysfunction through a variety of signaling 
pathways. TMAO functions as a switch that activates pro-in-
flammatory cascades, leading to arterial damage that allows 
the cholesterol to enter the arterial walls and subsequent 
plaque formation. A study using cultured human aortic endo-
thelial and vascular smooth muscle cells reported that the ex-
pression of various inﬂammatory cytokines and adhesion mol-
ecules was upregulated by TMAO, mediated in part via the nu-
clear factor-κB signaling pathway.40,41
Measurement of TMAO
Plasma TMAO levels vary widely both within and between indi-
viduals. A number of factors affect the circulating TMAO levels, 
including age, diet, gut microbial ﬂora, liver FMO enzymes, 
high-sensitivity C-reactive protein, and kidney function. Aside 
from the traditional protein-based biomarkers, there is an in-
creased interest on the development of analysis methods for 
newer metabolite-based biomarkers, including TMAO.3 Liquid 
chromatography-tandem mass spectrometry is considered as 
the gold standard method for the quantiﬁcation of TMAO, as it 
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enables high-accuracy, -precision, and -throughput analyses 
suitable for the needs of clinical diagnostic practices.42 
A harmful, protective, or diagnostic 
marker? 
Although a considerable evidence suggests that TMAO plays a 
role in the development and pathogenesis of CVD, its precise 
role is still an issue of debate. Some studies have found no re-
lationship between increased circulating TMAO levels and in-
creased risk of MACEs, perhaps due to the differences in age, 
risk factors, geographic location, or dietary habits of the indi-
viduals in their respective cohorts.
For example, the aforementioned Chinese study demonstrat-
ed that patients with a history of large artery atherosclerotic 
stroke or TIA had lower TMAO levels than asymptomatic ath-
erosclerotic patients.20 Similarly, a study conducted in Norway 
found no association between TMAO levels and carotid athero-
sclerosis or cardiovascular mortality.43 A population-based 
study of adults between 33 and 55 years reported that plasma 
TMAO was not associated with the 10-year incidence or pro-
gression of coronary artery calcium or intima-media thick-
ness.44 Thus, these data suggest that TMAO may not be the 
“culprit” but may be considered as a potential biomarker. High 
levels of circulating TMAO may reﬂect changes in the composi-
tion of the gut microbiota which increase disease susceptibility. 
Accumulation of TMAO in a disease state may be caused by 
the adaptation of cells to stress. Thus, TMAO would represent a 
disease marker rather than a mediator.9
Although many researchers have recognized the harmful ef-
fects of TMAO, others have suggested that it plays a beneficial 
role. One group suggested that TMAO functions as a naturally 
occurring osmolyte, protecting cells against the harmful effects 
of various stressors, for example, by counteracting the dena-
turing activity of urea by enhancing the stability of cellular 
proteins.45 Furthermore, TMAO slows the formation of aortic 
atherosclerotic lesions in apolipoprotein E knockout mice.46 
These data suggest that TMAO plays a role in preventing the 
development of atherosclerosis in humans.
Fish consumption is well known for its cardioprotective attri-
butes in humans. However, it causes higher levels of circulating 
TMAO than consumption of either eggs or beef. One study re-
ported that plasma TMAO levels increased within 15 minutes of 
consuming ﬁsh, which suggests that dietary TMAO is absorbed 
without processing by gut microbes.9 These conflicting data 
make it difficult to fully elucidate the relationship between CVD 
and dietary and gut microbe-mediated TMAO production.47 
Therapeutic strategy
TMAO appears to be a novel and potentially modiﬁable risk 
factor for stroke. The potential roles played by diet and drugs in 
reducing TMAO levels have emerged. 
Diet
Decreased dietary consumption of L-carnitine and choline has 
been shown to decrease TMAO levels.39 Likewise, consumption 
of the Mediterranean or vegetarian diet reportedly aids in re-
ducing TMAO production. 
Exercise
Exercise can alter the microbiota diversity and distribution in 
humans.48 Voluntary exercise ameliorates obesity and metabol-
ic disorders. An animal study showed that voluntary exercise 
normalizes the plasma TMAO levels and prevents cardiac dys-
function in western diet-induced obese mice. This effect was 
reversed by concomitant administration of TMAO and abrogat-
ed the beneﬁcial effects.49 
Microbiota
Several bacterial species that colonize the human gut have 
been shown to reduce TMAO levels. Thus, manipulation of the 
composition of commensal bacteria in the gut could be a novel 
therapeutic approach for preventing and treating CVD by mod-
ulating TMAO production. Therefore, probiotic formulations 
specifically tailored to this purpose could serve as the basis of 
a therapeutic strategy for treating CVD.36
Antibiotics
Healthy subjects treated with oral broad-spectrum antibiotics 
that induce suppression of the intestinal microbiota exhibited 
reduced plasma TMAO levels after the phosphatidylcholine 
challenge. The TMAO levels increased 1 month after cessation 
of antibiotic treatment.7 However, the potential undesirable 
side effects associated with the antibiotic treatment, in addi-
tion to the risk of the emergence of antibiotic-resistant bacte-
ria make this approach less than the ideal.
Aspirin
Low-dose aspirin treatment attenuates both the degree of 
TMAO elevation and platelet hyperresponsiveness.50 The mech-
anisms by which aspirin exerts these effects have yet to be 
elucidated; however, it is thought that aspirin affects the com-
position of the gut microbiota.
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FMO inhibitors 
Studies on animal models demonstrated that insulin or anti-
sense oligonucleotide-mediated suppression of the hepatic en-
zyme FMO3 leads to a reduction in circulating TMAO levels and 
prevents hypercholesterolemia and atherosclerosis. FMO3 inhi-
bition may be accompanied by several untoward side effects, 
including hepatic inflammation and noxious fish ordor.10,11
Resveratrol 
Resveratrol (RSV) is a natural polyphenol found in grapes and 
berries. Compared with the control mice, markedly lower levels 
of serum TMA and TMAO were found in the mice treated with 
RSV and fed with choline.51
Meldonium
Meldonium, an aza-analogue of gamma-butyrobetaine (GBB), 
competes with GBB and L-carnitine and is the most potent 
substance commercially available for decreasing L-carnitine 
levels. The intestinal microbiota-dependent production of TMA/
TMAO from L-carnitine was significantly decreased following 
meldonium treatment. However, meldonium had no effect on 
either bacterial growth or bacterial uptake of L-carnitine.52
3,3-d`imethyl-1-butanol 
A 3,3-d`imethyl-1-butanol (DMB), which is a structural ana-
logue of choline found in balsamic vinegar, red wines, and 
some olive oils and grape seed oils, inhibits TMA production by 
suppressing the activity of microbial TMA lyases. Moreover, it 
inhibits enhanced formation of endogenous macrophage foam 
cells and atherosclerotic lesions associated with consumption 
of a choline-rich diet. Consumption of DMB suppresses the 
growth of bacteria in taxa associated with increased levels of 
plasma TMA and TMAO.53 
Future work
Most clinical studies on TMAO conducted recently have used a 
cross-sectional or cohort design, and few interventional studies 
have been reported. Thus, additional interventional studies are 
needed to determine with certainty the relationship between 
TMAO and CVD development and progression. Such studies 
could facilitate the development of a therapeutic strategy tar-
geting TMAO.
Conclusions
Considerable evidence suggests that TMAO is an important risk 
factor and prognostic marker for stroke and CVD. Increased 
TMAO generation promotes atherosclerosis, platelet activation, 
and inflammation. TMAO may be a central molecule in the re-
lationship of diet, genetics, the gut microbiota, and CVD.
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